Pfizer and Nektar reach agreement on Exubera

San Carlos-based Nektar Therapeutics (NKTR) has resolved a contract dispute with Pfizer Inc. (PFE) over its line of inhaled insulin products, the companies announced Tuesday.

Pfizer will pay Nektar $135 million to satisfy its obligations for contracts relating to Exubera, an inhaled insulin product, and agreed to transfer its remaining right to the product if Nektar finds another partner for its development and marketing, the compay said in a statement.

Pfizer announced it would discontinue Exhubera last month due to disappointing sales, taking a $2.8 billion charge in the third quarter as a result, according to the Associated Press.

The companies said they will continue to work together on PEGylated human growth hormone therapy for short stature and growth problems.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

SF police issue first citation for violating stay at home order to abortion protester

Ronald Konopaski, 86, cited outside Planned Parenthood for allegedly failing to shelter in place

Pier 39 aquarium staff furloughed — but what about the fish?

Aquarium of the Bay raising funds from public to keep up operations during shutdown

Help the San Francisco Examiner, SF Weekly continue our mission of providing free, local news

This week, I was faced with the heartbreaking task of reducing the hours — and therefore the pay — of the very journalists who report, write, edit and photograph that news.

San Francisco police begin issuing citations for failing to shelter in place

Officers to cite businesses, people who fail to heed warnings

Ride-hail drivers left idling by coronavirus shutdown looking for a lift

Bay Area ride-hail drivers are among those who have been hit hardest… Continue reading

Most Read